Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ABT | 8-K | bearish | 6/10 | Abbott reported Q3 2026 adjusted diluted EPS of $1.42, missing consensus of $1.64 by 13.4%, and revenue of $13.013B vs $ | Oct 21, 2026 |
| ABT | PRESS-RELEASE | neutral | 4/10 | Abbott reported Q3 2026 EPS of $1.42, a 0.4% beat versus the consensus estimate of $1.41, on revenue of $12.99B (in line | Oct 21, 2026 |
| ROIV | 8-K | bullish | 7/10 | Roivant and its subsidiary Priovant announced positive Phase 3 results for brepocitinib in non-infectious uveitis (NIU). | Oct 21, 2026 |
| GNPX | 8-K | neutral | 2/10 | Genprex issued a press release highlighting peer-reviewed mouse research on the TUSC2 tumor suppressor gene's role in br | Oct 21, 2026 |
| VVOS | 8-K | neutral | 4/10 | Vivos Therapeutics received a letter from Nasdaq on October 20, 2026 confirming compliance with the minimum stockholders | Oct 21, 2026 |
| MSLE | 6-K | neutral | 2/10 | Satellos Bioscience announced management participation in two upcoming investor conferences (Guggenheim Healthcare Innov | Oct 21, 2026 |
| RDHL | 6-K | neutral | 3/10 | RedHill Biopharma regained ex-North America rights to RHB-102 after terminating its license agreement with Hyloris Pharm | Oct 21, 2026 |
| TLSA | 6-K | neutral | 2/10 | Tiziana Life Sciences announced that management will attend the joint ACTRIMS-ECTRIMS meeting (MSToronto2026) in Toronto | Oct 21, 2026 |
| PBM | 6-K | mixed | 5/10 | Psyence Biomedical completed its backstop investment of $2.6 million in PsyLabs after both ibogaine milestones were met: | Oct 21, 2026 |
| RDY | 6-K | bullish | 5/10 | Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) in combination with cisplatin and paclitaxel for first-line | Oct 21, 2026 |
| GSK | 6-K | bullish | 7/10 | GSK announced FDA approval of Hibsago (bepirovirsen) for chronic hepatitis B, a first-in-class antisense oligonucleotide | Oct 21, 2026 |
| IPHA | 6-K | neutral | 2/10 | Innate Pharma announced management participation in the Stifel Healthcare Conference (Nov 10-12, 2026) and Jefferies Glo | Oct 21, 2026 |
| HCM | 6-K | bullish | 7/10 | HUTCHMED closed the exclusive license agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted the | Oct 21, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K on October 21, 2026, solely to furnish a Notice of Annual General Meeting and pro | Oct 21, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a 6-K disclosing changes to CEO Dr. David Stamler's remuneration package, effective October | Oct 21, 2026 |
| GTBP | EFFECT | bearish | 6/10 | GT Biopharma's S-1 registration (File No. 333-299408) became effective on October 20, 2026, covering up to 9,723,057 sha | Oct 21, 2026 |
| DRMA | EFFECT | bearish | 6/10 | Dermata Therapeutics' S-3 shelf registration (File No. 333-299391) was declared effective on October 20, 2026, enabling | Oct 21, 2026 |
| ORKA | CLUSTER | neutral | 3/10 | Two insiders at Oruka Therapeutics sold a total of $534K in open-market sales within a week. The CMO exercised and sold | Oct 20, 2026 |
| ADIL | 10-Q/A | bearish | 7/10 | Adial Pharmaceuticals filed Amendment No. 1 to its Form 10-Q for the quarter ended June 30, 2026, primarily to respond t | Oct 20, 2026 |
| PDSB | 3 | neutral | 2/10 | Bruce Wendel filed a Form 3 initial statement of beneficial ownership with PDS Biotechnology Corp, indicating he has bec | Oct 20, 2026 |
| MRK | PTAB-TRIAL | neutral | 3/10 | The PTAB granted institution of inter partes review in IPR2026-00374, allowing Merck (as petitioner Merck Sharp & Dohme | Oct 20, 2026 |
| PDSB | 8-K | neutral | 4/10 | PDS Biotechnology filed an updated corporate presentation deck on October 20, 2026, highlighting clinical data for its t | Oct 20, 2026 |
| ADIL | S-3/A | bearish | 7/10 | Adial Pharmaceuticals filed Amendment No. 1 to its S-3 registration statement to register up to 25,148,970 shares of com | Oct 20, 2026 |
| TLX | 6-K | bullish | 7/10 | Telix Pharmaceuticals reported Q3 2026 group revenue of US$245 million, up 19% YoY, driven by 30% growth in Precision Me | Oct 20, 2026 |
| TLX | PRESS-RELEASE | bullish | 6/10 | Telix reported Q3 2026 group revenue of $245M (+19% YoY), with Precision Medicine revenue up 30% to $201M, and reaffirme | Oct 20, 2026 |
| MTEX | 8-K | bearish | 6/10 | Mannatech dismissed BDO USA as its independent auditor and engaged CBIZ CPAs, effective October 15, 2026. The filing not | Oct 20, 2026 |
| RARE | SC 13G | neutral | 3/10 | Madison Avenue Partners, LP and affiliated entities filed a Schedule 13G disclosing a 6.4% passive stake in Ultragenyx P | Oct 20, 2026 |
| CRSP | CLUSTER | bearish | 5/10 | Three insiders at CRISPR Therapeutics sold a total of ~$3.15M in open-market sales within a week, including the CEO ($2. | Oct 20, 2026 |
| MLYS | 3 | neutral | 2/10 | Kristine Peterson filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting zero shares owned | Oct 20, 2026 |
| ASBP | 8-K/A | mixed | 7/10 | Aspire-Lakewood Holdings, Inc. (ASBP) acquired Dura Driver Control Systems (DCS) for approximately $30 million in cash o | Oct 20, 2026 |